Johnson & Johnson announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018.
NEW BRUNSWICK, N.J., Aug. 8, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018. Mr. DelOrefice will report to Mr. Joseph Wolk, Executive Vice President and Chief Financial Officer of the Company.
Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business. In this role, he provided strategic financial leadership and counsel, which were integral in evolving the MD portfolio and commercial strategy to support our long-term growth. Previously, Mr. DelOrefice held various leadership positions across all three segments of Johnson & Johnson and many functions of the Company, and was instrumental in leading key mergers and acquisitions, negotiating critical licensing and managed care agreements and implementing major business restructurings.
“Chris is an accomplished leader, with a long track record of success. He consistently demonstrates Credo values and will continue to have a positive impact on Johnson & Johnson’s financial strength and stability and on the development of our future business leaders,” Mr. Wolk said.
Mr. DelOrefice holds a Bachelor of Science and MBA from Villanova University, and received his CPA certification from the Commonwealth of PA.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Note to Investors Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and descriptions of risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information, or future events or developments.
View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-announces-chris-delorefice-as-vice-president-of-investor-relations-300694405.html
SOURCE Johnson & Johnson
Company Codes: NYSE:JNJ
